牛牛AI助理已提取核心訊息
Avalo Therapeutics, Inc. has been the subject of a Schedule 13G/A amendment filing with the United States Securities and Exchange Commission (SEC) on December 31, 2023. The filing indicates that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Mr. Ortav Yehudai, have reported shared voting and dispositive power over 2,085 shares of Avalo Therapeutics' common stock, which represents 0.26% of the company's class of securities. The shares in question are associated with warrants that are subject to a Beneficial Ownership Cap, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding common stock. The filing, dated February 14, 2024, also includes a joint filing agreement between the reporting persons, indicating their intention to file this statement jointly in accordance with SEC regulations. The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest, and the filing certifies that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
Avalo Therapeutics, Inc. has been the subject of a Schedule 13G/A amendment filing with the United States Securities and Exchange Commission (SEC) on December 31, 2023. The filing indicates that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Mr. Ortav Yehudai, have reported shared voting and dispositive power over 2,085 shares of Avalo Therapeutics' common stock, which represents 0.26% of the company's class of securities. The shares in question are associated with warrants that are subject to a Beneficial Ownership Cap, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding common stock. The filing, dated February 14, 2024, also includes a joint filing agreement between the reporting persons, indicating their intention to file this statement jointly in accordance with SEC regulations. The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest, and the filing certifies that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
Avalo Therapeutics, Inc.已成爲2023年12月31日向美國證券交易委員會（SEC）提交的附表13G/A修正案的主題。文件顯示，Great Point Partners, LLC以及醫學博士傑弗裏·傑伊博士和Ortav Yehudai先生報告了對Avalo Therapeutics普通股的2,085股的共享投票權和處置權，普通股佔該公司證券類別的0.26％。有關股票與受實益所有權上限約束的認股權證有關，如果認股權證的所有權超過已發行普通股的9.99％，則無法行使認股權證。該文件日期爲2024年2月14日，還包括申報人之間的聯合申報協議，表明他們打算根據美國證券交易委員會的規定共同提交本聲明。申報人已放棄對股票的實益所有權，但金錢利益除外，該文件證明收購這些股份不是爲了改變或影響Avalo Therapeutics的控制權。
Avalo Therapeutics, Inc.已成爲2023年12月31日向美國證券交易委員會（SEC）提交的附表13G/A修正案的主題。文件顯示，Great Point Partners, LLC以及醫學博士傑弗裏·傑伊博士和Ortav Yehudai先生報告了對Avalo Therapeutics普通股的2,085股的共享投票權和處置權，普通股佔該公司證券類別的0.26％。有關股票與受實益所有權上限約束的認股權證有關，如果認股權證的所有權超過已發行普通股的9.99％，則無法行使認股權證。該文件日期爲2024年2月14日，還包括申報人之間的聯合申報協議，表明他們打算根據美國證券交易委員會的規定共同提交本聲明。申報人已放棄對股票的實益所有權，但金錢利益除外，該文件證明收購這些股份不是爲了改變或影響Avalo Therapeutics的控制權。
有用
沒用